ArticleMikrochimica acta2026
Ultrasensitive electrochemical dipstick lateral flow immunoassay for extracellular vesicle quantification using starch-iodine functionalized gold nanoparticles.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) have emerged as promising biomarkers for the diagnosis and monitoring of various diseases; however, their clinical application is limited by the need for sensitive and accessible detection platforms. In this study, a highly sensitive electrochemical lateral flow immunoassay (eLFIA) for the detection and accurate quantification of EVs in human plasma is presented. Using a polymer precipitation-based kit, EVs were isolated and determined by using iodine-doped starch-functionalized gold nanoparticle based immunochromatographic test. This strategy has never been used before for electrochemical coupling and it has been protected by an international patent. With this electrochemical approach, the biosensor achieved a detection limit of 9 EVs/µL, demonstrating significantly higher sensitivity than conventional optical methods and even exceeding the limits reported by more complex bulk widely-used techniques, such as Nanoparticle Tracking Analysis. In addition, validation on real biological samples confirmed the accuracy of the device with recoveries above 98%, underlining its robustness and reproducibility. This work establishes a versatile and efficient platform for EV detection that addresses key limitations of current immunoassays, positioning this eLFIA as a promising tool for clinical diagnostics. Furthermore, the proposed strategy has the potential to be adapted to other biomarkers, broadening its applicability to a variety of pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.